Iopidine (Apraclonidine)

Apraclonidine is a selective alpha‑2 adrenergic receptor agonist. By stimulating these receptors in the ciliary body, it reduces aqueous humor production and enhances uveoscleral outflow, leading to a decrease in intra‑ocular pressure.

The dosing regimen for Iopidine is determined by the prescribing ophthalmologist based on the individual patient’s condition and response. Typically, one to two drops are instilled in the affected eye(s) once or twice daily, but exact instructions must come from the prescriber.

Safety of apraclonidine in pregnancy and lactation has not been established, and the product is classified as pregnancy category unknown. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and under medical supervision.

To request Iopidine, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with beta‑blocker or prostaglandin analog eye drops, apraclonidine offers a distinct mechanism by reducing aqueous humor production via alpha‑2 agonism. It is often used as an adjunct rather than a first‑line monotherapy, providing additional pressure reduction when other agents alone are insufficient.

Iopidine eye drops should be stored at room temperature, below 25 °C, in the original container. Keep the bottle tightly closed, protect it from direct sunlight and moisture, and discard any remaining solution after the indicated period after opening, as per the label instructions.

Iopidine is applied topically to the eye. The patient should wash hands, tilt the head back, pull down the lower eyelid to form a pocket, and place the prescribed number of drops into the conjunctival sac. Avoid touching the tip of the bottle to the eye or any surface to maintain sterility.

The most serious risks include severe allergic reactions such as ocular edema, erythema, or systemic hypersensitivity, and rare cases of Stevens‑Johnson syndrome. Patients should also be monitored for significant drops in blood pressure or heart rate, especially if systemic alpha‑2 agonists are used concurrently.

Iopidine should not be used by individuals with known hypersensitivity to apraclonidine or any component of the formulation. Caution is advised in patients with severe cardiovascular disease, uncontrolled hypertension, or those taking systemic alpha‑2 agonists, as additive hypotensive effects may occur. Consultation with an eye care professional is essential before initiating therapy.